Roivant Sciences (NASDAQ:ROIV) Stock: Insider Eric Venker Sells 187,943 Shares

Roivant Sciences Ltd. (NASDAQ:ROIV – Get Free Report) CEO Eric Venker sold 187,943 shares of the company’s stock in a transaction that occurred on Tuesday, November 10th. The stock was sold at an average price of $40.53, for a total value of $7,617,329.79. Following the sale, the chief executive officer directly owned 811,211 shares in the company, valued at $32,878,381.83. This trade represents a 18.81% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Eric Venker also recently made the following trade(s):

  • On Tuesday, November 3rd, Eric Venker sold 200,000 shares of Roivant Sciences stock. The shares were sold at an average price of $36.31, for a total value of $7,262,000.00.
  • On Wednesday, October 28th, Eric Venker sold 200,000 shares of Roivant Sciences stock. The shares were sold at an average price of $36.59, for a total transaction of $7,318,000.00.
  • On Tuesday, October 20th, Eric Venker sold 200,000 shares of Roivant Sciences stock. The shares were sold at an average price of $35.11, for a total transaction of $7,022,000.00.
  • On Wednesday, September 30th, Eric Venker sold 200,000 shares of Roivant Sciences stock. The stock was sold at an average price of $36.62, for a total transaction of $7,324,000.00.
  • On Friday, August 28th, Eric Venker sold 200,000 shares of Roivant Sciences stock. The shares were sold at an average price of $35.77, for a total transaction of $7,154,000.00.

Roivant Sciences Price Performance

Roivant Sciences stock traded down $1.86 during mid-day trading on Thursday, reaching $39.99. 8,744,046 shares of the company’s stock traded hands, compared to its average volume of 8,291,942. Roivant Sciences Ltd. has a 12-month low of $19.96 and a 12-month high of $42.50. The stock has a 50 day moving average of $37.20 and a two-hundred day moving average of $32.16.

Institutional Investors Weigh In On Roivant Sciences

Institutional investors have recently made changes to their positions in the company. Wellington Management Group LLP boosted its stake in shares of Roivant Sciences by 179.0% during the 2nd quarter. Wellington Management Group LLP now owns 2,687,870 shares of the company’s stock worth $95,124,000 after purchasing an additional 1,724,588 shares during the period. Maverick Capital Ltd. bought a new position in Roivant Sciences during the 1st quarter valued at about $45,066,000. Assenagon Asset Management S.A. grew its holdings in Roivant Sciences by 18.2% during the 2nd quarter. Assenagon Asset Management S.A. now owns 8,362,952 shares of the company’s stock valued at $295,965,000 after purchasing an additional 1,286,464 shares during the last quarter. Affinity Asset Advisors LLC grew its holdings in Roivant Sciences by 64.7% during the 1st quarter. Affinity Asset Advisors LLC now owns 2,800,000 shares of the company’s stock valued at $77,560,000 after purchasing an additional 1,100,000 shares during the last quarter. Finally, Sumitomo Mitsui Trust Group Inc. purchased a new stake in Roivant Sciences in the 3rd quarter worth about $35,624,000. Institutional investors own 64.76% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms have recently weighed in on ROIV. HC Wainwright boosted their target price on shares of Roivant Sciences from $47.00 to $48.00 and gave the stock a “buy” rating in a report on Tuesday. TD Cowen reaffirmed a “buy” rating on shares of Roivant Sciences in a report on Wednesday, October 21st. Sanford C. Bernstein upgraded Roivant Sciences to a “strong-buy” rating in a research report on Wednesday, July 29th. Stifel Nicolaus began coverage on Roivant Sciences in a research report on Wednesday, September 16th. They issued a “buy” rating and a $51.00 price target for the company. Finally, Cantor Fitzgerald reissued an “overweight” rating on shares of Roivant Sciences in a research note on Thursday, September 24th. One investment analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $46.64.

View Our Latest Research Report on ROIV

About Roivant Sciences

(Get Free Report)

Roivant Sciences is a biopharmaceutical company that develops medicines through a network of subsidiary companies, which it calls “Vants.” These businesses focus on advancing drug candidates in areas such as immunology, oncology, neuroscience and rare diseases. Founded in 2014, Roivant has built and supported subsidiaries to develop treatments, manage clinical programs and pursue partnerships. Its portfolio has included both internally developed candidates and medicines licensed from other companies.

Recommended Stories

Insider Buying and Selling by Quarter for Roivant Sciences (NASDAQ:ROIV)

Receive News & Ratings for Roivant Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Roivant Sciences and related companies with MarketBeat.com's FREE daily email newsletter.